

Οργάνωση:  
Ελληνική Εταιρεία Επιστημόνων-  
Εργαζομένων Ακτινοθεραπείας

Σε συνεργασία:  
Παθολογικό Ογκολογικό Τμήμα  
Γ.Α.Ν.Π. ΜΕΤΑΞΑ

Υπό την αιγίδα:



ΙΣΧΥΣ ΕΝ ΤΗ ΕΝΩΣΕΙ

ΣΥΝΔΥΑΣΜΕΝΗ

Αντιμετώπιση  
του Καρκίνου

07 - 08 Οκτωβρίου 2022

ΛΑΕΔ

(Λέσχη Αξιωματικών Ενόπλων Δυνάμεων)

ΑΘΗΝΑ

ΠΡΟΓΡΑΜΜΑ

Οι χορηγοί είναι 16  
Μέλη Συνεργαζόμενης  
Εταιρείας Εκπαίδευσης  
(SME-CPD)

© 2022 E.C.S. EVENT & TRAVEL SOLUTIONS

ακτινοθεραπεία των HPV  
θετικών καρκίνων του  
στοματοφάρυγγα


Ιωάννης Γεωργακόπουλος  
Ακτινοθεραπευτής Ογκολόγος

# epidemiology


- globally 2017:
  - 890000 new cases (5.3 % of all cancers)
  - 507000 deaths (5.3% of all cancer deaths)
- 1990 to 2017, incidence rates for larynx and nasopharyngeal cancers decreased, whereas they increased for other pharyngeal cancers and lip/oral cavity cancers

# epidemiology


Laryngeal cancers




Nasopharyngeal cancers



Oral cavity cancers



Other pharyngeal cancers



# risk factors

- tobacco
- alcohol
- chronic viral infection (HPV, EBV)
- betel nut chewing
- male gender
- genetic susceptibility
- occupational exposure
- malnutrition
- poor dental care
- mechanical irritation

# treatment modalities

surgery

radiotherapy

chemotherapy

new agents

**as single modality or in combination**

(generally recommended for the approximately 30 to 40% of patients who present with early-stage disease, stage I or II)

**combined modality treatment**

(generally recommended for the approximately 60% of patients with locally or regionally advanced disease at diagnosis)

**alone or in combination with RT, ChTRT**

# considerations in decision making

- pretreatment considerations
  - comorbidities
  - malnutrition
  - oral health
- morbidity of treatment

# major issues regarding (ChT)RT in locally advanced HNCa

- induction ChT
- induction ChT vs. concurrent chemoradiotherapy
- adjuvant ChT
- cisplatin bolus vs. weekly administration
- cisplatin vs. carboplatin
- Cetuximab plus radiotherapy
- other EGFR inhibitors plus chemoradiation
- Cetuximab vs. cisplatin for definitive chemoradiation
- immunotherapy plus chemoradiation

# guidelines

- major role of RT both in early & advanced stages
- plus ChT or other agents in multimodal setting  
for unresectable disease or organ preservation approaches



HPV related OPC

# HPV

- Gillison et al, 2000 reported PCR detection of HPV DNA with OPC
- distinct clinical profile
  - younger, Caucasian, non-tobacco smoking, male
  - marijuana intake, multiple sex partners, oral sex
  - tonsil and base of tongue with high predilection for nodal spread
  - exceptionally responsive to all treatments
- correlation with HIV + and anogenital HPV +
- 70% of oropharyngeal Ca and incidence is rising unlike other HNSCC